^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HLX35

    i
    Other names: HLX35, BNA035
    Associations

    News

    Trials
    Company:
    Binacea Pharma, Fosun Pharma
    Drug class:
    EGFR inhibitor, CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    2years
    Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, Binacea Pharma, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CD4 (CD4 Molecule)
    |
    HLX35
    3years
    Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Binacea Pharma, Inc.
    Clinical • New P1 trial
    |
    CD4 (CD4 Molecule)
    |
    HLX35